163 related articles for article (PubMed ID: 24955582)
1. The study of the intercellular trafficking of the fusion proteins of herpes simplex virus protein VP22.
Xue X; Huang J; Wang H
PLoS One; 2014; 9(6):e100840. PubMed ID: 24955582
[TBL] [Abstract][Full Text] [Related]
2. Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.
Rutjes SA; Bosma PJ; Rohn JL; Noteborn MH; Wesseling JG
J Mol Med (Berl); 2003 Sep; 81(9):558-65. PubMed ID: 12879152
[TBL] [Abstract][Full Text] [Related]
3. Engineered cell therapy for sustained local myocardial delivery of nonsecreted proteins.
Bian J; Kiedrowski M; Mal N; Forudi F; Penn MS
Cell Transplant; 2006; 15(1):67-74. PubMed ID: 16700331
[TBL] [Abstract][Full Text] [Related]
4. Intercellular trafficking of VP22, a herpes simplex virus type 1 tegument protein.
Bamdad T; Bell JC
Iran Biomed J; 2007 Jan; 11(1):53-7. PubMed ID: 18051705
[TBL] [Abstract][Full Text] [Related]
5. Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.
Lai Z; Han I; Zirzow G; Brady RO; Reiser J
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11297-302. PubMed ID: 11027330
[TBL] [Abstract][Full Text] [Related]
6. Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein.
Beerens AM; Rots MG; de Vries EF; Haisma HJ
Int J Mol Med; 2007 May; 19(5):841-9. PubMed ID: 17390091
[TBL] [Abstract][Full Text] [Related]
7. Evidence for intercellular trafficking of VP22 in living cells.
Lemken ML; Wolf C; Wybranietz WA; Schmidt U; Smirnow I; Bühring HJ; Mack AF; Lauer UM; Bitzer M
Mol Ther; 2007 Feb; 15(2):310-9. PubMed ID: 17235309
[TBL] [Abstract][Full Text] [Related]
8. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.
Liu CS; Kong B; Xia HH; Ellem KA; Wei MQ
J Gene Med; 2001; 3(2):145-52. PubMed ID: 11318113
[TBL] [Abstract][Full Text] [Related]
9. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.
Fang B; Xu B; Koch P; Roth JA
Gene Ther; 1998 Oct; 5(10):1420-4. PubMed ID: 9930348
[TBL] [Abstract][Full Text] [Related]
10. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
11. VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.
Jin G; Zhou Y; Chai Q; Zhu G; Xu F; Liu F
J Cancer Res Clin Oncol; 2013 Mar; 139(3):475-83. PubMed ID: 23180018
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.
Wills KN; Atencio IA; Avanzini JB; Neuteboom S; Phelan A; Philopena J; Sutjipto S; Vaillancourt MT; Wen SF; Ralston RO; Johnson DE
J Virol; 2001 Sep; 75(18):8733-41. PubMed ID: 11507218
[TBL] [Abstract][Full Text] [Related]
13. Intercellular trafficking of VP22-GFP fusion proteins.
Elliott G; O'Hare P
Gene Ther; 1999 Jan; 6(1):149-51. PubMed ID: 10341888
[TBL] [Abstract][Full Text] [Related]
14. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
Zavaglia D; Lin EH; Guidetti M; Pluquet O; Hainaut P; Favrot MC; Coll JL
J Gene Med; 2005 Jul; 7(7):936-44. PubMed ID: 15754307
[TBL] [Abstract][Full Text] [Related]
15. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread.
Perkins SD; Hartley MG; Lukaszewski RA; Phillpotts RJ; Stevenson FK; Bennett AM
Vaccine; 2005 Mar; 23(16):1931-40. PubMed ID: 15734065
[TBL] [Abstract][Full Text] [Related]
16. Bcl-xL Genetic Modification Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cell Transplantation in the Treatment of Heart Infarction.
Xue X; Liu Y; Zhang J; Liu T; Yang Z; Wang H
Stem Cells Int; 2015; 2015():176409. PubMed ID: 26074971
[TBL] [Abstract][Full Text] [Related]
17. Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting.
Aints A; Güven H; Gahrton G; Smith CI; Dilber MS
Gene Ther; 2001 Jul; 8(14):1051-6. PubMed ID: 11526452
[TBL] [Abstract][Full Text] [Related]
18. VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
Sheridan PJ; Lawrie A; Crossman DC; Holt CM; Newman CM
J Gene Med; 2005 Mar; 7(3):375-85. PubMed ID: 15543525
[TBL] [Abstract][Full Text] [Related]
19. Intercellular spread of GFP-VP22.
Aints A; Dilber MS; Smith CI
J Gene Med; 1999; 1(4):275-9. PubMed ID: 10738560
[TBL] [Abstract][Full Text] [Related]
20. The major tegument structural protein VP22 targets areas of dispersed nucleolin and marginalized chromatin during productive herpes simplex virus 1 infection.
López MR; Schlegel EF; Wintersteller S; Blaho JA
Virus Res; 2008 Sep; 136(1-2):175-88. PubMed ID: 18584907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
